These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 348078)

  • 1. Patterns of resistance and therapeutic synergism among alkylating agents.
    Schabel FM; Trader MW; Laster WR; Wheeler GP; Witt MH
    Antibiot Chemother (1971); 1978; 23():200-15. PubMed ID: 348078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitrosoureas: a review of experimental antitumor activity.
    Schabel FM
    Cancer Treat Rep; 1976 Jun; 60(6):665-98. PubMed ID: 782694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.
    Griswold DP; Trader MW; Frei E; Peters WP; Wolpert MK; Laster WR
    Cancer Res; 1987 May; 47(9):2323-7. PubMed ID: 3567926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and L-phenylalanine mustard.
    Schmid FA; Otter GM; Stock CC
    Cancer Res; 1980 Mar; 40(3):830-3. PubMed ID: 7471099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies with 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. III. Biochemical and therapeutic effects in L1210 leukemias sensitive and resistant to alkylating agents: comparison with melphalan, cyclophosphamide, and BCNU.
    Schabel FM; Trader MW; Laster WR; Shaddix SC; Brockman RW
    Cancer Treat Rep; 1976 Sep; 60(9):1325-33. PubMed ID: 1016968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.
    Schabel FM; Trader MW; Laster WR; Corbett TH; Griswold DP
    Cancer Treat Rep; 1979; 63(9-10):1459-73. PubMed ID: 291480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.
    Institóris E; Szikla K; Otvös L; Gál F
    Cancer Chemother Pharmacol; 1989; 24(5):311-3. PubMed ID: 2758560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
    Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug sensitivity of methylnitrosourea- and 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea-resistant L1210 lines.
    Schmid FA; Otter GM; Chen CF
    Cancer Res; 1986 Sep; 46(9):4469-71. PubMed ID: 3731103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo.
    Harrison SD; Brockman RW; Trader MW; Laster WR; Griswold DP
    Invest New Drugs; 1987 Dec; 5(4):345-51. PubMed ID: 3436739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA; Herman TS; Tanaka J; Eder JP; Holden SA; Bubley G; Coleman CN; Frei E
    Cancer Res; 1991 Feb; 51(4):1086-91. PubMed ID: 1825474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L1210 leukemia hybrids isolated after fusion of alkylating agent-resistant sublines.
    Schmid FA; Otter GM; Hirano I
    Leuk Res; 1988; 12(1):67-70. PubMed ID: 3357349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E; Teicher BA; Holden SA; Cathcart KN; Wang YY
    Cancer Res; 1988 Nov; 48(22):6417-23. PubMed ID: 3180059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.
    Harrison SD; Plowman J; Dykes DJ; Waud WR; Griswold DP
    Cancer Chemother Pharmacol; 1990; 25(6):425-9. PubMed ID: 2311170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
    Ayash L; Korbut T; Herman TS; Teicher BA
    Cancer Lett; 1991 Dec; 61(1):7-14. PubMed ID: 1764699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met ethoxy HCl, a new chemotherapeutic agent active against drug-resistant tumor cell lines.
    Yagi MJ; Chin SE; Scanlon KJ; Holland JF; Bekesi JG
    Biochem Pharmacol; 1985 Jul; 34(13):2347-54. PubMed ID: 4040366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma.
    Holden SA; Teicher BA; Ara G; Herman TS; Coleman CN
    J Natl Cancer Inst; 1992 Feb; 84(3):187-93. PubMed ID: 1542129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of alkylating agents and other drugs on the accumulation of melphalan by murine L1210 leukaemia cells in vitro.
    Martin AD; Beer RW; Bosanquet AG; Gilby ED
    Biochem Pharmacol; 1982 Sep; 31(17):2727-32. PubMed ID: 7138568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of isocyanates in the toxicity of antitumour haloalkylnitrosoureas.
    Gibson NW; Hickman JA
    Biochem Pharmacol; 1982 Sep; 31(17):2795-800. PubMed ID: 7138575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.